Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013

By: Benzinga
Seattle Genetics (Nasdaq: SGEN ) today presented interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including acute
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.